10-KFiled 13 Nov 2026Industrials
Adient plcADNT
Annual report (10-K), FY2026
The reported numbers improved.
The shares became cheaper on AIR's value read.
The price trend weakened.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 1 week back · Material filings: 447 · All filings: 661
Friday 13 Nov76 filings read · 31 material
10-KFiled 13 Nov 2026Industrials
Adient plcADNT
Annual report (10-K), FY2026
The reported numbers improved.
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 13 Nov 2026All industries
8-K · Items 1.01, 3.03 — Material agreement
CNO Financial amended its Section 382 Rights Agreement, extending the expiration date to November 2029 and updating purchase price and preferred stock terms. The plan protects tax net operating loss carryforwards by deterring ownership stakes of 4.99% or more without board approval.
No notable change in AIR's read.
10-QFiled 13 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 13 Nov 2026All industries
8-K · Items 1.01, 8.01 — Material agreement
CareTrust REIT entered into forward sale agreements for 19.55M shares at $36/share initial price. Underwriters borrowed and sold shares short. Company faces potential forced settlement and shareholder dilution if acceleration events occur.
The filings read less positively.
The gap narrowed — attention is catching up.
10-QFiled 13 Nov 2026All industries
Realloys Inc.ALOY
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 13 Nov 2026All industries
Contango Silver & Gold Inc.CTGO
8-K · Item 1.01 — Material agreement
Contango Silver & Gold entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald and co-agents, authorizing up to $75M in at-the-market common stock offerings. No shares have been sold; the company is not obligated to sell.
No notable change in AIR's read.
10-KFiled 13 Nov 2026All industries
Annual report (10-K), FY2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 13 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed as the filings read less positively.
The price trend weakened.
10-QFiled 13 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
10-QFiled 13 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 13 Nov 2026Banks
Chaince Digital Holdings Inc.CD
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
10-QFiled 13 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 13 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Jade Biosciences advanced multiple clinical programs ahead of schedule. JADE101 Phase 3 trial (EVERGREEN) initiating Q4 2026; JADE301 Phase 1 expected Q4 2026. Cash runway extended to Q4 2028 ($475.7M). Multiple clinical catalysts expected in 2027.
Progress is running ahead of attention.
10-QFiled 13 Nov 2026All industries
QXO, Inc.QXO
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 13 Nov 2026Industrials
Enovix CorpENVX
Quarterly report (10-Q), period ending 4 Oct 2026
Progress is running ahead of attention.
8-KFiled 13 Nov 2026All industries
SBC Medical Group Holdings IncSBC
8-K · Item 2.02 — Results of operations
Q3 2026: Revenue +35% YoY to $59M, operating income +66% to $26M, net income +22% to $16M. Adjusted EBITDA +66% to $28M with 47% margin. Clinic network expanded 36 locations to 293; patient visits +9% YoY.
No notable change in AIR's read.
10-QFiled 13 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 13 Nov 2026All industries
Aaon, Inc.AAON
8-K · Item 1.01 — Material agreement
AAON refinanced and expanded its senior credit facility, increasing total borrowing capacity from $600M to $1.2B (including accordion), extending maturity to 2031, and adding a $100M supply chain financing program to enhance liquidity and support growth.
No notable change in AIR's read.
10-QFiled 13 Nov 2026All industries
SBC Medical Group Holdings IncSBC
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 13 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 13 Nov 2026Banks
8-K · Items 1.01, 2.03 — Material agreement
Enova's subsidiary ODAS IV issued $500.3M in fixed-rate asset-backed notes (Series 2026-2) secured by small business loans. Proceeds used to purchase loans from OnDeck subsidiary. Seventh series issued under existing securitization program with weighted average coupon of 6.58%.
No notable change in AIR's read.
8-KFiled 13 Nov 2026All industries
Realloys Inc.ALOY
8-K · Item 2.02 — Results of operations
REalloys executed non-binding term sheet with U.S. Army for heavy rare earth processing facility at Tooele Army Depot; advanced metallization and processing programs targeting North American rare earth metal production beginning 2027; maintains $116.2M cash, virtually debt-free.
No notable change in AIR's read.
8-KFiled 13 Nov 2026Software / SaaS
Science Applications International CorpSAIC
8-K · Items 1.01, 2.03 — Material agreement
SAIC closed a $500M private offering of 6.750% Senior Notes due 2034, netting ~$493M after fees. Proceeds used to redeem all outstanding 4.875% Senior Notes due 2028, with remainder for general corporate purposes.
The shares became cheaper on AIR's value read.
10-QFiled 13 Nov 2026All industries
Contango Silver & Gold Inc.CTGO
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 13 Nov 2026Industrials
National Presto Industries IncNPK
Quarterly report (10-Q), period ending 4 Oct 2026
No notable change in AIR's read.
8-KFiled 13 Nov 2026All industries
Contango Silver & Gold Inc.CTGO
8-K · Item 2.02 — Results of operations
Q3-2026 results show significant operational headwinds: gold production down 56% YoY due to mine pit transition and mill processing delays; net loss of $23.0M vs. prior-year loss of $5.4M; cash position declined to $56.6M from $64.8M year-end.
No notable change in AIR's read.
10-QFiled 13 Nov 2026Semiconductors
Everspin Technologies Inc.MRAM
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 13 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 13 Nov 2026Industrials
Trimas CorpTRS
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed — attention is catching up.
10-QFiled 13 Nov 2026All industries
XMax Inc.XMAX
Quarterly report (10-Q), period ending 30 Sep 2026
The filings read less positively.
The price trend weakened.
8-KFiled 13 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026 results show $38.7M net loss (vs. $35.3M prior year), increased debt to $275M, and negative stockholders' equity of $85.9M. Offset by $2M Pfizer license revenue, R&D cost reduction, and advancing clinical milestones for two programs.
The gap narrowed as the filings read less positively.
The price trend weakened.
Thursday 12 Nov175 filings read · 119 material
8-KFiled 12 Nov 2026Industrials
Heartflow, Inc.HTFL
8-K · Item 2.02 — Results of operations
Heartflow reported Q3 2026 revenue of $72.9M (+57% YoY), beating expectations with 83.6% gross margin. Company raised full-year 2026 guidance to $262–264M (+49–50% growth) from prior $246–250M, citing accelerating U.S. revenue, expanding installed base, and strong Plaque Analysis adoption.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026All industries
Transcontinental Realty Investors IncTCI
8-K · Item 2.02 — Results of operations
Q3 2026 net loss of $0.1M ($0.02/share) vs. prior-year net income of $0.7M ($0.08/share). Revenue up 8% but net operating loss doubled to $2.4M due to $1.4M increase in lease-up property expenses. Interest income declined $0.7M.
No notable change in AIR's read.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 12 Nov 2026All industries
QXO, Inc.QXO
8-K · Item 2.02 — Results of operations
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Crescent Biopharma reported Q3 2026 results with significant clinical progress: completed dose escalation in Phase 1/2 ASCEND trial (125+ patients dosed), initiated CR-002 Phase 1/2 APOLLO trial, and achieved 9 IND clearances with partner Kelun-Biotech. Multiple data readouts expected in 2027.
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Industrials
Quarterly report (10-Q), period ending 3 Oct 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
The gap closed as the filings read less positively.
The price trend weakened.
10-QFiled 12 Nov 2026Biotech
Absci CorpABSI
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026All industries
Aveanna Healthcare Holdings, Inc.AVAH
Quarterly report (10-Q), period ending 3 Oct 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026Industrials
National Vision Holdings, Inc.EYE
Quarterly report (10-Q), period ending 3 Oct 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 12 Nov 2026All industries
Fermi Inc.FRMI
8-K · Item 2.02 — Results of operations
Fermi secured ~$200M upfront commitment from investment-grade hyperscaler for 600 MW at Project Matador, with additional $90M materials agreement pending. Demonstrates commercial traction and de-risks project funding.
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Biotech
SELLAS Life Sciences Group, Inc.SLS
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Nektar advanced rezpegaldesleukin into Phase 3 development across atopic dermatitis and alopecia areata with all three ZENITH AD trials initiated and ZENITH AA on track for December start. Cash position strengthened to $952.9M from $245.8M year-end 2025.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026Industrials
NeuroPace IncNPCE
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $23.1M missed expectations with only 1% RNS growth. Full-year guidance slashed from $99.5–$101.5M to $91–$92M. CEO cited account-level disruptions and field organization changes. Net loss improved to $3.3M from $4.9M YoY, but trajectory remains concerning.
Attention caught up with the documented progress.
The price trend weakened.
10-QFiled 12 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 12 Nov 2026Semiconductors
8-K · Item 2.02 — Results of operations
T1 Energy signed 1.58GW new offtake contracts post-Section 232 proclamation, raised 2027 production guidance to 5.3GW (sold out), and advanced G2_Austin financing negotiations. Q3 net loss of $34.7M reflects intentional inventory build for 2027 deliveries.
No notable change in AIR's read.
8-KFiled 12 Nov 2026Biotech
Taysha Gene Therapies, Inc.TSHA
8-K · Item 2.02 — Results of operations
Taysha reports Q3 2026 results with strong TSHA-102 safety data (33 patients, no severe SAEs/DLTs), completed BLA-enabling manufacturing campaign meeting specifications, and expects pivotal trial interim data and FDA feedback in H1 2027.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026All industries
Corteva, Inc.CTVA
8-K · Item 2.02 — Results of operations
Q3 2026 results show 9% organic sales decline and 17% EBITDA decline. Brazil market significantly weaker than anticipated due to farmer liquidity constraints and pricing pressure. Full-year guidance reduced; EBITDA now $1.1–1.125B (vs. prior guidance), EPS $0.76–$0.80.
Market attention has faded.
The price trend weakened.
8-KFiled 12 Nov 2026Industrials
National Vision Holdings, Inc.EYE
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 4.8% to $510.5M with adjusted operating margin expanding 320 bps to 7.3%. Adjusted diluted EPS more than doubled to $0.30 from $0.13. Company accelerating new store openings one year ahead of plan.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 12 Nov 2026Semiconductors
Applied Optoelectronics, Inc.AAOI
8-K · Items 1.01, 1.02 — Material agreement
AAOI acquired three Houston buildings (736,216 sq ft) for $102.25M by exercising purchase options from May 2026 leases. Leases terminated without early penalty. Transaction converts operating leases to owned real estate.
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Immix reported 89% complete response rate in NEXICART-2 with potential 98% future rate. Strong cash position ($340.9M) extends runway to mid-2028. BLA submission planned mid-2027; NEXICART-3 initiation H1 2027. Key hires in technical operations and regulatory affairs.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026Semiconductors
Axt IncAXTI
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 12 Nov 2026Biotech
Taysha Gene Therapies, Inc.TSHA
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
Absci CorpABSI
8-K · Items 2.02, 8.01 — Results of operations
Absci reported Q3 2026 results with ABS-201 HEADLINE trial on track for December interim proof-of-concept data in pattern hair loss. Announced Phase 2 endometriosis trial details (mid-2027 initiation) and appointed experienced Chief Commercial Officer. Cash runway extends to H2 2028.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Industrials
Amprius Technologies, Inc.AMPX
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 12 Nov 2026All industries
American Integrity Insurance Group, Inc.AII
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: Exchange Written Premium grew 27% YoY to $1.33B; adjusted EBITDA $71.3M (25.4% margin); 26 new MGAs added. Pending Thoma Bravo acquisition expected to close H1 2027. GAAP net loss of $9.2M offset by adjusted net income of $38.2M.
Market attention has faded.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Altimmune reports Q3 2026 results with $480M cash position. PERFORMA Phase 3 MASH trial progressing as planned; positive RECLAIM Phase 2 AUD data presented at AASLD. FDA End-of-Phase 2 meeting scheduled December 2026 for AUD program. RESTORE Phase 2 ALD enrollment complete.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
8-K · Items 2.02, 8.01 — Results of operations
SpyGlass Pharma completed first implantations of BIM-DRS (next-generation drug delivery system), announced four-year efficacy data for lead BIM-IOL System (37% IOP reduction, 86% off drops), acquired IOL manufacturer AVS for $13M, and maintains $215.8M cash runway through 2028.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026Biotech
Kardigan, Inc.KARD
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Biotech
4D Molecular Therapeutics, Inc.FDMT
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026All industries
8-K · Items 1.01, 8.01 — Material agreement
Eastman Chemical issued $300M of 5.500% notes due 2030 in a public offering. Net proceeds of ~$297.7M will be used for general corporate purposes including working capital, capex, and debt repayment.
No notable change in AIR's read.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Kodiak reported positive Phase 3 results for two lead programs (Zenkuda and tabirafusp-ted) in wet AMD, with Zenkuda meeting primary endpoint and 54% of patients achieving 6-month dosing. BLA submissions planned for Q4 2026 and Q2 2027. KSI-101 pivotal data expected December 2026.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026All industries
Suburban Propane Partners LpSPH
8-K · Item 2.02 — Results of operations
SPH reported FY2026 net income of $109.0M ($1.63/unit) and Adjusted EBITDA growth of 2.2% to $284.0M. Strong propane demand, RNG capacity expansion, debt reduction, and 7.7% distribution increase announced.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026All industries
Transcontinental Realty Investors IncTCI
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 12 Nov 2026Industrials
Astronics CorpATRO
Quarterly report (10-Q), period ending 3 Oct 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026All industries
WEX Inc.WEX
8-K · Items 1.01, 2.03 — Material agreement
WEX amended its credit agreement, extending maturity to November 2031, increasing revolving facility to $1.7B and term loan to $900M, with repriced interest margins tied to leverage ratios.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 12 Nov 2026All industries
Quarterly report (10-Q), period ending 27 Sep 2026
Progress is running ahead of attention.
8-KFiled 12 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Biotech
Anaptysbio, IncANAB
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 12 Nov 2026All industries
Corteva, Inc.CTVA
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
10-KFiled 12 Nov 2026Biotech
Arrowhead Pharmaceuticals, Inc.ARWR
Annual report (10-K), FY2026
Progress is running ahead of attention.
8-KFiled 12 Nov 2026All industries
8-K · Item 2.02 — Results of operations
EPC reported Q4 FY2026 organic sales growth of 3.1% and adjusted EPS of $0.78 (+50% YoY). Full-year adjusted EPS of $1.93 (+6.6% YoY) met guidance. FY2027 outlook projects organic sales growth of 1.0–3.0% and adjusted EPS of $1.85–$2.15.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
Intellia Therapeutics, Inc.NTLA
8-K · Item 2.02 — Results of operations
Intellia hosted investor webcast on lonvo-z (CRISPR therapy for HAE). BLA accepted by FDA with priority review; PDUFA goal date March 10, 2027. Phase 3 HAELO trial achieved primary endpoint (62% attack-rate reduction) and key secondary endpoints with favorable safety. No advisory committee planned.
Progress is running ahead of attention.
10-QFiled 12 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 12 Nov 2026Semiconductors
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 12 Nov 2026Biotech
Arrowhead Pharmaceuticals, Inc.ARWR
8-K · Item 2.02 — Results of operations
ARWR reported FY2026 results with REDEMPLO commercial momentum (63% QoQ prescription growth, 950 cumulative prescriptions), FDA STAR program entry for plozasiran sHTG indication, successful Phase 3 data, and refinanced debt at lower rates with improved terms.
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 12 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
10-QFiled 12 Nov 2026Industrials
Ondas Inc.ONDS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 12 Nov 2026All industries
Hagerty, Inc.HGTY
8-K · Items 1.01, 8.01 — Material agreement
Hagerty Holding Corp. completed a secondary offering of 10M shares at $14.85/share, with a 30-day overallotment option for 1.5M additional shares. Hagerty receives no proceeds; net proceeds fund a trust redemption.
No notable change in AIR's read.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026Industrials
Enovix CorpENVX
8-K · Item 2.02 — Results of operations
Enovix reported Q3 2026 revenue of $11.0M (+38% YoY), record non-GAAP gross margin of 34.5%, and issued FY2027 guidance of $65–85M revenue (+75% to +128% YoY). Drone/defense pipeline grew 18% to $216M. Company restructured, retired $128M of 2030 Notes at 36% discount, and reduced annual costs by $8.5M.
Progress is running ahead of attention.
10-QFiled 12 Nov 2026Biotech
Erasca, Inc.ERAS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026All industries
Tetra Tech IncTTEK
8-K · Items 2.02, 8.01 — Results of operations
Tetra Tech reported record Q4 and FY2026 EPS, 13% YoY backlog growth to $4.67B, 90bps EBITDA margin expansion, and an 11% dividend increase—the 46th consecutive double-digit increase. Strong government contract wins totaling $1.9B support confidence in FY2027 guidance.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
MeiraGTx reported Q3 2026 results with major regulatory milestones: MAA submission for bota-vec (XLRP) expected December 2026, BLA submission Q1 2027. Strong cash position ($184.7M) supports operations into H2 2028. Multiple clinical programs advancing; Lilly partnership generates revenue and milestone potential.
No notable change in AIR's read.
8-KFiled 12 Nov 2026All industries
United States Antimony CorpUAMY
8-K · Item 2.02 — Results of operations
Q3 2026 revenue up 16% YoY to $10.1M; gross profit surged 113% to $4.3M with margin expanding to 42%. Antimony pounds sold jumped 68% driven by DLA contract acceptance of 162k pounds. October DLA shipments added $3.6M revenue. Zeolite revenue grew 55% YoY.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026All industries
8-K · Item 1.01 — Material agreement
Astec agreed to sell Roadtec and Carlson businesses to Komatsu for $75M enterprise value. Sale eliminates operating losses, expected to improve adjusted EBITDA margin ~200 bps and be accretive to EPS. Closes Q1 2027.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026Industrials
Anteris Technologies Global Corp.AVR
8-K · Item 2.02 — Results of operations
Anteris reported Q3 2026 progress on PARADIGM Trial enrollment across multiple countries, assumed occupancy of Minnesota manufacturing facility for production scaling, and appointed new CFO. Operating cash outflow was $22.9M.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Tamboran achieved first gas sales from Beetaloo Basin in September 2026, delivering 40 TJ/d to NT Government under fixed-price contract. Well performance confirms deliverability expectations with IP30 rates of 8.8–10.2 MMcf/d. Infrastructure completed on budget; ~US$180M pro forma cash balance.
Market attention has faded.
The price trend weakened.
10-QFiled 12 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Silence Therapeutics announced acquisition by Merck KGaA (expected Q1 2027), reported positive Phase 2 SANRECO divesiran results with best-in-class dosing profile, and strengthened cash position to $247.7M via capital raise. Q3 operating losses improved significantly YoY.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026All industries
8-K · Item 2.02 — Results of operations
NOAA delayed final certification decision to mid-December 2026 (from end-October) due to 1,600 public comments, with no identified application deficiencies. TMC and Allseas advancing capital-light phased production approach. U.S. government funding discussions ongoing for Brownsville processing facility.
Progress is running ahead of attention.
8-KFiled 12 Nov 2026Biotech
4D Molecular Therapeutics, Inc.FDMT
8-K · Item 2.02 — Results of operations
4DMT completed enrollment and randomization of 4FRONT-2 Phase 3 trial for 4D-150 in wet AMD; initiated 4SIGHT Phase 3 in DME; presented positive 2-year data; hired Chief Regulatory Officer. Topline data expected Q2 2027 and H2 2027.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 12 Nov 2026Biotech
8-K · Item 1.01 — Material agreement
Prime Medicine completed an underwritten public offering of ~35.7M shares at $3.50/share, raising ~$134.7M net proceeds. Funds will support Wilson disease and alpha-1 antitrypsin deficiency programs, R&D, and general corporate purposes.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 12 Nov 2026Software / SaaS
NIQ Global Intelligence plcNIQ
8-K · Items 2.02, 8.01 — Results of operations
NIQ exceeded guidance for 6th consecutive quarter with positive GAAP EPS ($0.12/share) for first time since IPO. Achieved 2.9x net leverage one quarter ahead of plan. Board authorized $150M share repurchase program.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.